Tesamorelin vs Sermorelin: Choosing the Right Peptide for Your Research Choose Tesamorelin When: The primary research endpoint is visceral adipose tissue (VAT) reduction Rapid, measurable IGF-1 elevation is needed within a short protocol window Studying metabolic syndrome, abdominal obesity, or lipodystrophy models Extended protocol stability is required (tesamorelin resists enzymatic degradation better) Research budget supports a higher-cost compound for a shorter, intensive protocol Choose Sermorelin When: The focus is long-term endocrine system support and hormonal homeostasis Sleep architecture and recovery pathways are the primary study variables Anti-aging, collagen synthesis, or longevity markers are being investigated A physiological, pulsatile GH release pattern is required to preserve feedback loops Cost efficiency over a long-duration protocol is a consideration The comparison extends beyond just these two peptides
Responsiveness of human bronchial fibroblasts and epithelial cells from asthmatic and non-asthmatic donors to the transforming growth factor-1 in epithelial-mesenchymal trophic unit model
Psoriatic plaques exhibit acanthosis (epidermal hyperplasia) and inflammatory infiltrates composed of dermal dendritic cells, macrophages, T cells, and neutrophils histologically (33)
Eikady AI, Hussein RA, Abu-Zinadah OA, et al
